Longeveron LLC (LGVN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Longeveron LLC (LGVN) has a cash flow conversion efficiency ratio of -0.273x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.37 Million) by net assets ($16.03 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See LGVN defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Longeveron LLC - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Longeveron LLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Longeveron LLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Longeveron LLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Country Club Hospitality & Holidays Limited
NSE:CCHHL
|
0.014x |
|
TURBOMECANICA S.A.
RO:TBM
|
-0.014x |
|
Tek Seng Holdings Bhd
KLSE:7200
|
0.104x |
|
Damai Sejahtera Abadi Tbk PT
JK:UFOE
|
0.101x |
|
Calgro M3 Holdings Ltd
JSE:CGR
|
-0.059x |
|
Logic Instrume
PA:ALLOG
|
-0.125x |
|
Sun Summit Minerals Corp
V:SMN
|
-0.490x |
|
BG T&A Co
KQ:046310
|
0.070x |
Annual Cash Flow Conversion Efficiency for Longeveron LLC (2018–2025)
The table below shows the annual cash flow conversion efficiency of Longeveron LLC from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see LGVN company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.67 Million | $-18.64 Million | -3.285x | -418.52% |
| 2024-12-31 | $21.89 Million | $-13.87 Million | -0.634x | +77.52% |
| 2023-12-31 | $6.74 Million | $-19.00 Million | -2.819x | -313.74% |
| 2022-12-31 | $20.50 Million | $-13.97 Million | -0.681x | -164.81% |
| 2021-12-31 | $37.45 Million | $-9.64 Million | -0.257x | +78.70% |
| 2020-12-31 | $1.96 Million | $-2.36 Million | -1.208x | -124.58% |
| 2019-12-31 | $4.45 Million | $-2.39 Million | -0.538x | +29.22% |
| 2018-12-31 | $6.81 Million | $-5.18 Million | -0.760x | -- |
About Longeveron LLC
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; com… Read more